NOV 2 8 2000

Attorney Docket No: COMA-037/00US 341260/D19078 BF #/6/4 DT 12-5-00

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 21, 2000.

Hanna Hacham

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (VED)

In re application of Christian DEVAUX, et al.

DEC 0 4 2000

1-21-00

Serial No.:

09/648,557

Examiner:

TECH CENTER 1600/2900

Filed:

August 25, 2000

Art Unit:

1614

For:

INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF

**HIV INFECTIONS** 

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

- 1. Applicant hereby submits this Information Disclosure Statement in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.
- 2. Applicant makes no representation that a search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.
  - No copies enclosed: The publications listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the PTO as recited in the Information Disclosure Statement Transmittal that accompanies this paper. In accordance with the provisions of 37 C.F.R. 1.98(d), no copies of these publications are being provided.
  - [X] <u>Copies enclosed:</u> Copies of the publications listed on the enclosed PTO Form 1449 are being provided with this Information Disclosure Statement.



The enclosed publications were cited in a foreign examination report in a related case. A copy of the search report and the cited references are attached hereto.

- [] The search report is not in the English language and a translation of the search report is enclosed.
- At least one of the enclosed publications is not in the English language.
  - [ ] English translation(s) are enclosed.
  - [ ] Enclosed is an explanation of the relevance of non-English publications for which an English translation is not available.
    - [ ] The explanation is in the form of an English language search report.

The subject application is believed patentable over any of the above references.

By:

Cooley Godward LLP

Attn: Patent Group Five Palo Alto Square 3000 El Camino Real

Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663

ML:hh

Enclosures:

1. Form PTO 1449


2. Copies of references cited on Form PTO-1449

COOLEY GODWARD LLP

Marcella Lillis, Ph.D.

Respectfully submitted,

Reg. No. 36,583



**PATENT** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 21, 2000.

: Hanna Hacham

Hanna Hacham

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of Christian DEVAUX, et al.

Serial No.:

09/648,557

Examiner:

DEC 0 4 2000

Filed:

August 25, 2000

Art Unit:

1614

TECH CENTER 1600/2900

For:

2.

[X]

INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF

**HIV INFECTIONS** 

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

1.	Transmitted herewith are:			
	[X]	Information Disclosure Statement		
	[X]	PTO Form 1449		
	[X]	Copies of publications listed on the PTO Form 1449		
	[]	English translation of foreign language reference(s)		
	[ ]	No copies of publications listed on the PTO Form 1449 are being provided as this application claims continuation status to application Serial No.  and copies of the listed publications were provided in the parent application.		
	[]	Copy of foreign examination report		
		[ ] English translation of foreign examination report		

This Information Disclosure Statement is filed before the later of:

		[X]	three months from the filing date of this national application;			
		[]	three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or			
		[]	the mailing date of a first office action on the merits.			
	In acc	cordanc	e with 37 CFR 1.97(b), no fee is required.			
3.	[]	This Information Disclosure Statement is filed after the events noted it paragraph 2, but before either:				
		[]	Final action under 37 CFR 1.113, or			
		[]	Notice of Allowance under 37 CFR 1.311.			
	In acc	In accordance with 37 CFR 1.97(c) also enclosed is:				
		[]	Fee under 37 CFR 1.17(p) in the amount of \$240.00, or			
		[]	Statement. See below.			
4.	[]		This Information Disclosure Statement is filed before the payment of the issue fee, but after either:			
		[]	Final action under 37 CFR 1.113, or			
		[]	Notice of Allowance under 37 CFR 1.311.			
	In acc	In accordance with 37 CFR 1.97(d) also enclosed is:				
		[]	Statement as specified in 37 CFR 1.97(e)			
		[]	Petition requesting consideration of the Information Disclosure Statement; and			
		[]	The petition fee set forth in 37 CFR 1.17(i) in the amount of \$130.00.			
5.	Statement. The undersigned states:					
	[]	Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or				
	[]	No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.				



Fees

[X] No fee is required.

[X] The Commissioner is hereby authorized to charge any underpayment or credit any overpayment of the patent application processing fees under 37 CFR 1.17 associated with this communication to Deposit Account No. 03-3117.

Cooley Godward LLP Attn: Patent Group Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663

ML:hh

Respectfully submitted, COOLEY GODWARD LLP

By: Marcella Lillis, Ph.D.

Reg. No. 36,583